, Volume 35, Issue 2, pp 458-459
Date: 05 Oct 2010

Managing BRCA Mutation Carriers in China

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Inherited mutations in BRCA1 or BRCA2 (BRCA1/2) genes confer a high lifetime risk of ~75% for breast cancer development and ~20–60% for ovarian cancer in women who test positive for these mutations. In the United States and Europe genetic testing is widely used and can identify these high-risk women with BRCA1/2 mutation carriers who more often select prophylactic surgery rather than surveillance. However, data on family history, genetic testing, and preventive intervention in Asian countries such as China are scarce.

The report by Kwong et al. [1] in the July 2010 issue of World Journal of Surgery comes to provide useful information on hereditary breast-ovarian cancer (HBOC) syndrome in China. A total of 31 patients with breast and/or ovarian cancer were found to have positive genetic testing for BRCA1/2 mutations. Forty-one tested family members without breast or ovarian cancer also had positive genetic testing. Most females patients (85.7%) opted for breast surveillance, and only 23. ...